All Stories

  1. Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry
  2. CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility
  3. Titanium dioxide nanoparticles enhance production of superoxide anion and alter the antioxidant system in human osteoblast cells
  4. Blood biocompatibility of surface-bound multi-walled carbon nanotubes
  5. Pegylation Increases Platelet Biocompatibility of Gold Nanoparticles
  6. Pharmacological and toxicological effects of co-exposure of human gingival fibroblasts to silver nanoparticles and sodium fluoride
  7. Nitric oxide-matrix metaloproteinase-9 interactions: Biological and pharmacological significance
  8. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells
  9. Platelets and photodynamic cancer therapy
  10. Nanoparticle Adhesion to the Cell Membrane and Its Effect on Nanoparticle Uptake Efficiency
  11. MMP inhibition by barbiturate homodimers
  12. Targeted Delivery of Transferrin-Conjugated Liposomes to an Orthotopic Model of Lung Cancer in Nude Rats
  13. Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance
  14. Mechanisms of Toxicity of Amorphous Silica Nanoparticles on Human Lung Submucosal Cells in Vitro: Protective Effects of Fisetin
  15. Approaches to the safety assessment of engineered nanomaterials (ENM) in food
  16. Differential inhibition of tumour cell‐induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin
  17. Fisetin prevents fluoride- and dexamethasone-induced oxidative damage in osteoblast and hippocampal cells
  18. Design of Barbiturate–Nitrate Hybrids that Inhibit MMP-9 Activity and Secretion
  19. Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis
  20. The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation
  21. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets
  22. Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects
  23. N-Substituted homopiperazine barbiturates as gelatinase inhibitors
  24. Polystyrene nanoparticles activate ion transport in human airway epithelial cells
  27. Elucidation of flow‐mediated tumour cell‐induced platelet aggregation using an ultrasound standing wave trap
  28. Analysis of platelet function: role of microfluidics and nanodevices
  29. Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling
  30. Extracorporeal life support
  31. The effect of new aspirin prodrugs on blood platelet and tumor cells in an ‘in vitro’ study
  32. Isosorbide-Based Aspirin Prodrugs: Integration of Nitric Oxide Releasing Groups
  33. Platelet compatibility of PLGA, chitosan and PLGA–chitosan nanoparticles
  34. NANOINTERACT: A rational approach to the interaction between nanoscale materials and living matter?
  35. A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery
  36. Effect of Nanoparticulate Matter on Transepithelial Ion Fluxes in Calu-3 Cells.
  37. Characterisation of the R3/1 cell line as an alveolar epithelial cell model for drug disposition studies
  38. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK
  39. Matrix metalloproteinases in platelet function: coming of age
  40. Role of metalloproteinases in platelet function
  41. Nanoparticles: pharmacological and toxicological significance
  42. Selectins – potential pharmacological targets?
  43. Increased Alveolar and Plasma Gelatinases Activity during Postpump Syndrome: Inhibition by Inhaled Nitric Oxide
  44. Platelet Dysfunction in Asphyxiated Newborn Piglets Resuscitated with 21% and 100% Oxygen
  45. Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients
  46. Nanoparticle‐induced platelet aggregation and vascular thrombosis
  47. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: A pilot clinical study
  48. Platelet–leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases
  49. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation
  50. Metaloproteinasas de matriz en enfermedades del tracto gastrointestinal
  51. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder
  52. Membrane type‐1 matrix metalloproteinase stimulates tumour cell‐induced platelet aggregation: role of receptor glycoproteins
  53. Metaloproteinasas de matriz en enfermedades del tracto gastrointestinal
  54. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina.
  55. Differential release of matrix metalloproteinase‐9 and nitric oxide following infusion of endotoxin to human volunteers
  56. Increased matrix metalloproteinase activity after canine cardiopulmonary bypass is suppressed by a nitric oxide scavenger
  57. Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study
  58. Identification, regulation and role of tissue inhibitor of metalloproteinases‐4 (TIMP‐4) in human platelets
  59. Mechanisms of action of proteinase‐activated receptor agonists on human platelets
  60. Role of von Willebrand factor in tumour cell‐induced platelet aggregation: differential regulation by NO and prostacyclin
  61. Pharmacological characteristics of solid‐phase von Willebrand factor in human platelets
  62. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts
  63. Effects of LY117018 and the Estrogen Analogue, 17α-Ethinylestradiol, on Vascular Reactivity, Platelet Aggregation, and Lipid Metabolism in the Insulin-Resistant JCR:LA-cp Male Rat: Role of Nitric Oxide
  64. Therapeutic Effect of Phenantroline in Two Rat Models of Inflammatory Bowel Disease
  65. Vascular Matrix Metalloproteinase-2–Dependent Cleavage of Calcitonin Gene-Related Peptide Promotes Vasoconstriction
  66. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates
  67. Matrix Metalloproteinase-2 Contributes to Ischemia-Reperfusion Injury in the Heart
  68. Inhmition of matrix metalloproteinases(MMPs)prevents tissue injury and fibrotic complications in two rat models of inflammatory bowel disease
  69. Nitric Oxide and Platelet Function
  70. Regulation of Platelet Function
  71. The role of nitric oxide in the regulation of ion channels in airway epithelium: Implications for diseases of the lung
  72. Vascular Matrix Metalloproteinase-2 Cleaves Big Endothelin-1 Yielding a Novel Vasoconstrictor
  73. Inhibition of matrix metalloproteinase MMP-2 activates chloride current in human airway epithelial cells
  74. Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by S-nitrosoglutathione
  75. Differential Inhibition of Platelet Aggregation by Indomethacin and Inhaled Nitric Oxide in Critically Ill Infants
  76. NO effect on hemostasis
  77. Nitric Oxide-Mediated Regulation of Platelet Function
  78. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia‐induced lung injury in newborn rats
  79. Inhibition of nitric oxide generation unmasks vascular dysfunction in insulin‐resistant, obese JCR:LA‐cp rats
  80. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates
  81. Nitric oxide: Implications for placental biology
  82. Nitric oxide and platelet function: Implications for neonatology
  83. 1.P.104 The role of nitric oxide in the vasculopathy of the JCR:LA-cp rat
  84. Release of gelatinase A during platelet activation mediates aggregation
  86. Regulation of Platelet Function by Nitric Oxide
  87. Regulation of Platelet Function by Nitric Oxide and Other Nitrogen-and Oxygen-Derived Reactive Species
  88. Nitric oxide: Implications for placental biology
  89. [9] Nitric oxide in platelets
  90. Nitric oxide— biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis
  91. The formation of nitric oxide donors from peroxynitrite
  92. Direct measurement of nitric oxide in human beings
  93. Systemic effects of S‐nitroso‐glutathione in the human following intravenous infusion.
  94. Megakaryocytes From Patients With Coronary Atherosclerosis Express the Inducible Nitric Oxide Synthase
  95. Nitric Oxide: Biological Mediator, Modulator and Effector
  96. The Role of Nitric Oxide in Vascular Haemostasis and Thrombosis: Implications for Septicaemia and Cell Damage
  97. Platelet Regulation and Damage in Vascular Thrombotic and Septic Disorders
  98. Nitric oxide and the pathogenesis of heart muscle disease
  99. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty
  100. Nitric oxide donors inhibit platelet spreading on surfaces coated with fibrinogen but not with fibronectin
  101. Comparative pharmacology of analogues of S‐nitroso‐N‐acetyl‐dl‐penicillamine on human platelets
  102. Nitric oxide in the clinical arena
  103. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide
  104. Direct Electrochemical Measurement of Nitric Oxide Released from Human Platelets
  105. Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase
  106. The Biological and Pharmacological Role of Nitric Oxide in Platelet Function
  107. Nitric oxide synthase activities in human myocardium
  108. S‐nitroso‐glutathione inhibits platelet activation in vitro and in vivo
  109. Modulation of platelet aggregation by an l-arginine-nitric oxide pathway
  110. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages
  111. Characterization of the l‐arginine: nitric oxide pathway in human platelets
  112. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
  113. Increased activity of circulating polymorphonuclear leukocytes in acute myocardial infarction
  114. Endothelium-derived relaxing factor
  115. Isolation and washing of human platelets with nitric oxide
  116. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium
  117. The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide
  119. Comparative pharmacology of endothelium‐derived relaxing factor, nitric oxide and prostacyclin in platelets
  120. Salicylates and 12-lipoxygenase activity in human washed platelets
  121. The Problems and the Promise of Prostaglandin Influences in Atherogenesis
  122. An ultrastructural study of stored human platelets after washing using prostacyclin
  123. Inhibition of human platelet aggregation by vitamin K
  124. An improved method for washing of human platelets with prostacyclin
  125. Prostacyclin prolongs viability of washed human platelets
  126. The use of prostacyclin in the separation from plasma and washing of human platelets
  127. Conversion of exogenous arachidonic acid to prostaglandins in the pulmonary circulation in vivo A human and animal study
  128. On the mechanism of angiotensin II induced release of prostacyclin
  129. Disaggregatory action of phosphodiesterase inhibitors
  130. Angiotensin-induced release of prostacyclin (PGI2) into circulation of anaesthetized cats
  131. Nitric Oxide, Platelet Function, Myocardial Infarction and Reperfusion Therapies
  132. The Nitric Oxide-Endothelin-1 Connection